AR123714A1 - Biofactores para el tratamiento y la profilaxis de la demencia - Google Patents
Biofactores para el tratamiento y la profilaxis de la demenciaInfo
- Publication number
- AR123714A1 AR123714A1 ARP210102785A ARP210102785A AR123714A1 AR 123714 A1 AR123714 A1 AR 123714A1 AR P210102785 A ARP210102785 A AR P210102785A AR P210102785 A ARP210102785 A AR P210102785A AR 123714 A1 AR123714 A1 AR 123714A1
- Authority
- AR
- Argentina
- Prior art keywords
- dementia
- prophylaxis
- treatment
- biofactors
- folates
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title abstract 3
- 238000011321 prophylaxis Methods 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 4
- 235000019152 folic acid Nutrition 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 2
- 229960000304 folic acid Drugs 0.000 abstract 2
- 239000011724 folic acid Substances 0.000 abstract 2
- 150000002224 folic acids Chemical class 0.000 abstract 2
- QWLHYYKDLOVBNV-UHFFFAOYSA-L magnesium orotate Chemical compound [Mg+2].[O-]C(=O)C1=CC(=O)NC(=O)N1.[O-]C(=O)C1=CC(=O)NC(=O)N1 QWLHYYKDLOVBNV-UHFFFAOYSA-L 0.000 abstract 2
- 229960000407 magnesium orotate Drugs 0.000 abstract 2
- 239000002775 capsule Substances 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008298 dragée Substances 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 230000004065 mitochondrial dysfunction Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000006188 syrup Substances 0.000 abstract 1
- 235000020357 syrup Nutrition 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- 235000012222 talc Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
La invención se refiere a un agente para el tratamiento y la profilaxis de la demencia (enfermedades) y la disfunción mitocondrial, en particular, a un suplemento medicinal o nutricional y su uso, que contiene una combinación de biofactores que comprende al menos orotato de magnesio y ácido fólico o folatos. Reivindicación 1: Agentes que comprenden orotato de magnesio y ácido fólico o folatos o tautómeros y sales de los mismos para su uso en la profilaxis y el tratamiento de la demencia. Reivindicación 8: Preparaciones farmacéuticas que contengan un agente para usar de acuerdo con cualquiera de las reivindicaciones 1 a 7, dado el caso junto con excipientes adecuados, en particular, en forma de gotas, jugo, jarabe, comprimidos, grageas, cápsulas, formulaciones de liberación prolongada, infusiones, ungüentos, emulsiones, talcos, polvos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20200644.1A EP3981407A1 (de) | 2020-10-07 | 2020-10-07 | Biofaktoren zur behandlung und prophylaxe von demenz |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123714A1 true AR123714A1 (es) | 2023-01-04 |
Family
ID=72801432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102785A AR123714A1 (es) | 2020-10-07 | 2021-10-07 | Biofactores para el tratamiento y la profilaxis de la demencia |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20240261286A1 (es) |
| EP (2) | EP3981407A1 (es) |
| JP (1) | JP2023545721A (es) |
| KR (1) | KR20230121996A (es) |
| CN (1) | CN116322695A (es) |
| AR (1) | AR123714A1 (es) |
| AU (1) | AU2021356119A1 (es) |
| BR (1) | BR112023006333A2 (es) |
| CA (1) | CA3198067A1 (es) |
| CL (1) | CL2023001016A1 (es) |
| CO (1) | CO2023004351A2 (es) |
| ES (1) | ES3010450T3 (es) |
| GE (2) | GEP20257780B (es) |
| HR (1) | HRP20250121T1 (es) |
| HU (1) | HUE070429T2 (es) |
| MD (1) | MD4225318T2 (es) |
| MX (1) | MX2023004107A (es) |
| PE (1) | PE20231320A1 (es) |
| PL (1) | PL4225318T3 (es) |
| RS (1) | RS66489B1 (es) |
| SM (1) | SMT202500116T1 (es) |
| TW (1) | TW202237121A (es) |
| WO (1) | WO2022074114A1 (es) |
| ZA (1) | ZA202304043B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| IL303519A (en) | 2020-12-10 | 2023-08-01 | Vertex Pharma | Cystic fibrosis treatment methods |
| JP2025529972A (ja) * | 2022-09-02 | 2025-09-09 | レックスファームテック カンパニー リミテッド | 新規ベンフォチアミンコリン塩 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6420342B1 (en) * | 2000-05-08 | 2002-07-16 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
| US20090285912A1 (en) * | 2008-05-16 | 2009-11-19 | Ramiro Rodriquez | Food Supplement and Method for Enhancing Athletic Performance |
| DE102009025549A1 (de) * | 2009-06-15 | 2010-12-16 | Werth Akupunktur Center | Zusammensetzung für den Transport von Orotsäure über die Bluthirnschranke |
| CN103113405B (zh) * | 2012-10-17 | 2016-03-02 | 上海日馨生物科技有限公司 | 苯磷硫胺多晶型体、制备方法及其应用 |
| US20150132273A1 (en) | 2013-11-09 | 2015-05-14 | Rhett Sean Daniels | Nutritional Compositions and Methods for Treating Cognitive Impairment |
| WO2017059895A1 (en) | 2015-10-07 | 2017-04-13 | Parthenogen Sagl | Dietary supplementation to achieve oxy-redox homeostasis and genomic stability |
| EP3443965A4 (en) | 2016-04-15 | 2020-02-19 | Hirokawa, Yoshihiro | MEANS FOR HEALING THE COGNITIVE FUNCTION |
| DE202017006840U1 (de) * | 2017-03-03 | 2018-07-26 | Glycana UG (haftungsbeschränkt) | Nahrungsergänzungsmittel umfassend einen Galaktose-haltigen Multivitamin-Mineralstoffkomplex |
-
2020
- 2020-10-07 EP EP20200644.1A patent/EP3981407A1/de not_active Withdrawn
-
2021
- 2021-10-07 WO PCT/EP2021/077684 patent/WO2022074114A1/de not_active Ceased
- 2021-10-07 RS RS20250134A patent/RS66489B1/sr unknown
- 2021-10-07 BR BR112023006333A patent/BR112023006333A2/pt unknown
- 2021-10-07 US US18/030,740 patent/US20240261286A1/en active Pending
- 2021-10-07 AR ARP210102785A patent/AR123714A1/es unknown
- 2021-10-07 GE GEAP202116242A patent/GEP20257780B/en unknown
- 2021-10-07 CN CN202180068999.1A patent/CN116322695A/zh active Pending
- 2021-10-07 PE PE2023001360A patent/PE20231320A1/es unknown
- 2021-10-07 MD MDE20230801T patent/MD4225318T2/ro unknown
- 2021-10-07 PL PL21798288.3T patent/PL4225318T3/pl unknown
- 2021-10-07 AU AU2021356119A patent/AU2021356119A1/en active Pending
- 2021-10-07 JP JP2023521188A patent/JP2023545721A/ja active Pending
- 2021-10-07 MX MX2023004107A patent/MX2023004107A/es unknown
- 2021-10-07 SM SM20250116T patent/SMT202500116T1/it unknown
- 2021-10-07 TW TW110137302A patent/TW202237121A/zh unknown
- 2021-10-07 ES ES21798288T patent/ES3010450T3/es active Active
- 2021-10-07 EP EP21798288.3A patent/EP4225318B1/de active Active
- 2021-10-07 HR HRP20250121TT patent/HRP20250121T1/hr unknown
- 2021-10-07 CA CA3198067A patent/CA3198067A1/en active Pending
- 2021-10-07 GE GEAP202516242A patent/GEAP202516242A/en unknown
- 2021-10-07 HU HUE21798288A patent/HUE070429T2/hu unknown
- 2021-10-07 KR KR1020237015178A patent/KR20230121996A/ko active Pending
-
2023
- 2023-03-31 ZA ZA2023/04043A patent/ZA202304043B/en unknown
- 2023-04-04 CO CONC2023/0004351A patent/CO2023004351A2/es unknown
- 2023-04-06 CL CL2023001016A patent/CL2023001016A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MD4225318T2 (ro) | 2025-02-28 |
| MX2023004107A (es) | 2023-08-07 |
| SMT202500116T1 (it) | 2025-05-12 |
| ZA202304043B (en) | 2024-04-24 |
| RS66489B1 (sr) | 2025-03-31 |
| KR20230121996A (ko) | 2023-08-22 |
| HRP20250121T1 (hr) | 2025-03-28 |
| TW202237121A (zh) | 2022-10-01 |
| EP4225318C0 (de) | 2024-11-13 |
| CN116322695A (zh) | 2023-06-23 |
| WO2022074114A1 (de) | 2022-04-14 |
| US20240261286A1 (en) | 2024-08-08 |
| CA3198067A1 (en) | 2022-04-14 |
| AU2021356119A9 (en) | 2024-10-03 |
| HUE070429T2 (hu) | 2025-06-28 |
| CO2023004351A2 (es) | 2023-07-10 |
| EP3981407A1 (de) | 2022-04-13 |
| GEAP202516242A (en) | 2025-02-10 |
| PE20231320A1 (es) | 2023-08-24 |
| GEP20257780B (en) | 2025-07-10 |
| ES3010450T3 (en) | 2025-04-03 |
| CL2023001016A1 (es) | 2023-11-17 |
| AU2021356119A1 (en) | 2022-04-14 |
| JP2023545721A (ja) | 2023-10-31 |
| EP4225318A1 (de) | 2023-08-16 |
| PL4225318T3 (pl) | 2025-04-07 |
| BR112023006333A2 (pt) | 2023-05-09 |
| EP4225318B1 (de) | 2024-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123714A1 (es) | Biofactores para el tratamiento y la profilaxis de la demencia | |
| US6733797B1 (en) | Neuroceutical for improving memory and cognitive abilities | |
| PE20190738A1 (es) | Formulacion novedosa para administracion por via oral | |
| CO6280475A2 (es) | Metodo para tratar la deficiencia de vitamina b12 | |
| ECSP066990A (es) | Formulaciones con liberación controlada de principio activo que contienen vardenafilo | |
| AR067184A1 (es) | Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica | |
| CL2021000793A1 (es) | Inhibición de la proteasa 30 específica de la ubiquitina (usp30) | |
| CL2021001536A1 (es) | 3,3- difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que las comprenden | |
| AU2003214059A1 (en) | Preparations containing folic acid, vitamin b6, and vitamin b12, and use thereof | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| ES2180446B1 (es) | Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil. | |
| ES2526359T3 (es) | Formulación galénica oral que comprende ketorolaco y vitaminas del complejo B, en la que la vitamina B6 se encuentra en una capa externa separada del resto de principios activos | |
| CL2020002369A1 (es) | Preparación farmacéutica o de complemento alimenticio a base de alfa-lactoalbúmina | |
| CO2024013759A2 (es) | Composición que comprende n-acetilcisteína, vitamina d y preferentemente glutatión, usos de la misma, y composiciones farmacéuticas y nutracéuticas de los mismos | |
| GT200600263A (es) | Regimen de dosificacion para prasugrel | |
| BR0112830A (pt) | Medicamento destinado especialmente a combater as disfunções sexuais | |
| CL2023000764A1 (es) | Formas farmacéuticas multipartículas que comprenden deutetrabenazina | |
| NO20044519L (no) | Hyperforinderivater, anvendelse derav samt formuleringer som inneholder dem | |
| AR009338A1 (es) | Composicion de dosis de unidad multivitaminica y usos de dicha composicion de dosis | |
| CL2025001338A1 (es) | Un producto farmacéutico para mejorar el rendimiento cognitivo de un sujeto. | |
| RU2016147455A (ru) | Способ лечения кожных проявлений склеродермии | |
| CL2024000781A1 (es) | Formas farmacéuticas multipartículas que comprenden deutetrabenazina | |
| DOP2025000253A (es) | Compuestos de derivados de ácido indazol propiónico sustituidos y usos de estos | |
| AR128051A1 (es) | Inhibidores de parp1 | |
| CL2017003178A1 (es) | Composición nutricional complementaria formada por ginseng rojo coreano, cafeina, bacillus coagulans, vitamina b6, vitamina b12, selenio, magnesio y excipientes farmacéutica y nuricionalmente aceptables, para mejorar el rendimiento físico y mental. |